Clinical Trials Logo

Liver Neoplasm clinical trials

View clinical trials related to Liver Neoplasm.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02599909 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

Start date: November 6, 2015
Phase:
Study type: Observational

Background: There are about 100 trillion microbial cells in a person s gut. This is called the human gut microbiota. When this is disrupted, it can lead to many diseases. Studies show that the gut microbiota in people with cancer is different than that found in healthy people. Researchers want to study links between the gut microbiota and the immune system in people with a liver disease called hepatocellular carcinoma (HCC). Objective: To study links between gut microbiota and the immune system in people with HCC. Eligibility: People at least 18 years old with HCC. They must be scheduled to have tumors removed by surgery. Design: - People having surgery for primary liver tumors at the Mount Sinai Medical Center will be screened for this study. - At the initial visit, blood, rectal swabs, urine, and stool will be collected. Participants will answer questions about their medical condition. - Before surgery, blood, rectal swabs, urine, and stool will be collected. This will be done at a routine visit. - When they have surgery, a piece of liver tissue with the tumor will be collected. This will be sent to the National Cancer Institute for tests. - After surgery, blood, rectal swabs, urine, and stool will be collected 3 times. This will be done at routine visits.

NCT ID: NCT00510627 Withdrawn - Clinical trials for Metastatic Liver Cancer

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

Prometheus
Start date: August 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.